The estimated Net Worth of Philip A Laskawy is at least $5.28 Million dollars as of 5 March 2024. Mr. Laskawy owns over 4,278 units of Covetrus stock worth over $515,619 and over the last 21 years he sold CVET stock worth over $4,201,893. In addition, he makes $560,000 as Independent Chairman of the Board at Covetrus.
Philip has made over 57 trades of the Covetrus stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 4,278 units of CVET stock worth $326,369 on 5 March 2024.
The largest trade he's ever made was exercising 30,000 units of Covetrus stock on 9 March 2011 worth over $1,327,800. On average, Philip trades about 1,327 units every 35 days since 2003. As of 5 March 2024 he still owns at least 24,565 units of Covetrus stock.
You can see the complete history of Mr. Laskawy stock trades at the bottom of the page.
Philip A. Laskawy serves as Independent Chairman of the Board of the Company. Mr. Laskawy joined the accounting firm of EY LLP (“EY”, formerly known as Ernst & Young LLP) in 1961 and served as a partner in the firm from 1971 to 2001, when he retired. Mr. Laskawy served in various senior management positions at EY, including Chairman and Chief Executive Officer, to which he was appointed in 1994. Mr. Laskawy is currently a Director of Henry Schein, having served on the Board since 2002 and as the Lead Independent Director since 2012. He is currently the Chair of Henry Schein’s nominating and governance committee and is a member of its audit committee. Since 2002, Mr. Laskawy has served as a member of the Board of Directors of Loews Corporation and as a member of its audit committee. Additionally, since 2008, he has served as a member of the Board of Directors of Lazard Ltd. and is Chair of its audit committee and a member of its compensation committee. Mr. Laskawy previously served on the American Institute of Certified Public Accountants to review and update rules regarding auditor independence. In 2006 and 2007, he served as Chairman and Vice Chairman of the International Accounting Standards Committee Foundation, which was created by the Securities and Exchange Commission and sets accounting standards in more than 100 countries, and he served as a member of the 1999 Blue Ribbon Committee on Improving the Effectiveness of Corporate Audit Committees. During the past five years, Mr. Laskawy served on the Board of Directors of General Motors Corporation and was the Non-Executive Chairman of Federal National Mortgage Association (Fannie Mae). Mr. Laskawy received a B.A. in Economics from the Wharton School of the University of Pennsylvania. As a Certified Public Accountant with over 50 years of experience.
As the Independent Chairman of the Board of Covetrus, the total compensation of Philip Laskawy at Covetrus is $560,000. There are 6 executives at Covetrus getting paid more, with Benjamin Wolin having the highest compensation of $4,065,210.
Philip Laskawy is 78, he's been the Independent Chairman of the Board of Covetrus since 2019. There are no older and 26 younger executives at Covetrus.
Philip's mailing address filed with the SEC is C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE, NY, 11747.
Over the last 5 years, insiders at Covetrus have traded over $10,243,394 worth of Covetrus stock and bought 11,744 units worth $216,180 . The most active insiders traders include Steven Paladino, Benjamin Wolin, and Philip A Laskawy. On average, Covetrus executives and independent directors trade stock every 10 days with the average trade being worth of $268,798. The most recent stock trade was executed by Rebecca Ann Kidd on 1 October 2022, trading 1,232 units of CVET stock currently worth $25,860.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Covetrus executives and other stock owners filed with the SEC include: